Canadian National Stock Exchange (CNSX)

Canadian National Stock Exchange (CNSX)

May 18, 2011 10:41 ET

CNSX: 2011-0510 New Listing-Pivotal Therapeutics Inc. (PVO)

TORONTO, ONTARIO--(Marketwire - May 18, 2011) - The common shares of Pivotal Therapeutics Inc. have been approved for listing on CNSX. The Company has 68,986,117 common shares outstanding with a public float of approximately 49.6 million shares.

Pivotal is a re-profiling specialty pharmaceutical company that creates novel uses for currently marketed or near market drugs or therapeutics. Pivotal's first product, VASCAZENTM, is a prescription-only medical food to be used for the clinical dietary management of cardiovascular disease in patients with documented coronary heart disease (CHD), deficient in blood omega-3 fatty acid, Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) levels.

Listing and disclosure documents for Pivotal Therapeutics Inc. will be available in the CNSX Listings Disclosure Hall (http://www.cnsx.ca/Page.asp?PageID=2013&AA_RecordID=373&SiteNodeID=211&BL_ExpandID=1391).

Trading Date: Thursday, May 19, 2011

Symbol: PVO

CUSIP: 72582E 10 4

ISIN: CA 72582E 10 4 3

Applications are being accepted for Market Makers for "PVO" (http://www.cnsx.ca/Page.asp?PageID=122&ContentID=658&SiteNodeID=190&BL_ExpandID=1399&BL_ExpandID=1399).

Contact Information